Liminatus Pharma, Inc. Class A Common Stock (LIMN) is a publicly traded Healthcare sector company. As of May 21, 2026, LIMN trades at $0.29 with a market cap of $8.40M and a P/E ratio of -0.43. LIMN moved -1.21% today. Year to date, LIMN is -72.50%; over the trailing twelve months it is -97.02%. Its 52-week range spans $0.16 to $33.66. Rallies surfaces LIMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Liminatus Pharma Raises $4M in 13.8M Share Offering with Warrants: Liminatus Pharma priced a best-efforts public offering of 13,813,000 common shares and warrants for 20,719,500 shares at $0.29 each, raising gross proceeds of $4.0 million. Full warrant exercise could provide an additional $6.0 million; net proceeds will fund working capital and corporate objectives.
| Metric | Value |
|---|---|
| Price | $0.29 |
| Market Cap | $8.40M |
| P/E Ratio | -0.43 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $33.66 |
| 52-Week Low | $0.16 |
| Volume | 83.47M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-10.21M |
| Gross Margin | 0.00% |
LIMN analyst coverage data. Average price target: $0.00.